Vertex regulatory update

VRTX said U.S. Patent No. 5,439,939 was issued to Children's Hospital Oakland Research Institute covering the use of VX-366 to treat genetic hemoglobin disorders. VX-366 is in development as an oral treatment of sickle cell anemia and beta thalassemia. The Cambridge, Mass., company has an exclusive license to the patent. ...